NCT04577300进行中（未招募）2 期
A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Visual Field MD at 12 Months
研究概览
简要总结
To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.
详细描述
A randomized, sham controlled, masked trial of up to 30 eyes will be recruited into the study. Participants with a qualifying study eye will be randomized after screening and baseline evaluations to receive 2 NT-501 ECT implants in the study eye (20 eyes), 1 NT-501 ECT implant (5 eyes) or a sham surgery (control arm; 5 eyes). No explant will be required. An examination for safety will occur one day and one week following implant and periodically thereafter for 24 months post-implant. Patients in the control arm may be offered 2 NT-501 ECT implants after the 12-month post-operative follow-up visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be medically able to undergo the testing required in the schedule of events (SOE).
- •Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) of -3 to -20 dB on Humphrey Visual Field 24-2 testing and two visual field tests of adequate quality with a maximum VFI variability of ± 10%
- •Residual visual field preservation including best-corrected visual acuity (BCVA) better than 20/200 in either eye.
- •Participant's eye pressure must be clinically stable, with IOP <
- •If a participant has two eyes meeting study criteria, the worse eye as determined by visual field index (VFI) or patient preference, will be deemed includable. If both eyes qualify and have the same VFI, a randomization procedure will assign one eye to the study.
- •Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
- •Females of childbearing potential must agree to use an effective form of birth control.
- •Participant must be determined by the presurgical anesthesia or medical team to be fit for ophthalmic surgery for the NT-501 ECT implant insertion.
排除标准
- •Participant is unable to comply with study procedures or followup visits.
- •Participant has other optic nerve or retinal degenerative disease causing vision loss, irrespective of whether it is currently treated or untreated.
- •Participant is likely to be offered glaucoma surgery in the study eye within 6 months of screening.
- •Participant has cataract-associated vision loss to less than 20/
- •Participant has a history of ocular herpes zoster.
- •Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.
- •Participant has evidence of corneal opacification or lack of optical clarity.
- •Participant has uveitis or other ocular inflammatory disease.
- •Participant is receiving systemic steroids or other immunosuppressive medications.
- •Participant has diabetic macular edema and/or diabetic retinopathy.
- •Participant has myopic degeneration.
- •Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.
- •Participant is pregnant or lactating.
- •Participant is on chemotherapy.
- •Participant has a history of malignancy other than basal cell carcinoma, unless it was treated successfully 2 years prior to inclusion in the trial.
- •Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments.
- •Any intraocular surgery of the study eye within 12 weeks prior to the screening visit
- •History of use of drugs with known retinal toxicity, at retinotoxic doses.
- •Patient has a history of multiple sclerosis.
研究组 & 干预措施
Dual Implantation
Experimental
Two NT-501 devices will be implanted in the study eye.
干预措施: NT-501 (Drug)
Single Implantation
Experimental
One NT-501 device will be implanted in the study eye.
干预措施: NT-501 (Drug)
Sham Implantation
Sham Comparator
No NT-501 devices will be implanted in the study eye.
干预措施: Sham comparator (Other)
结局指标
主要结局
Visual Field MD at 12 Months
时间窗: 12 months
Change from baseline in visual field through 12 months as assessed by Mean Deviation (MD).
次要结局
- Visual Field Index at 12 months(12 months)
- Visual Field PLR at 12 months(12 months)
研究者
Jeffrey L Goldberg
Professor
Stanford University
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)Visual AcuityGeographic AtrophyMacular DegenerationNCT02895815Janssen Pharmaceutical K.K.
已完成
2 期
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy PatientsType 2 Diabetes MellitusChronic Kidney DiseaseNCT01487109Concert Pharmaceuticals170
Unknown
2 期
A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04895345Chia Tai Tianqing Pharmaceutical Group Co., Ltd.25
Unknown
2 期
Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)Chronic Hepatitis bNCT04202653Tongji Hospital30
已完成
2 期
Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2Macular Telangiectasia Type 2NCT04729972Neurotech Pharmaceuticals33